Sensus Healthcare, Inc.

As of August 7, 2025, Sensus Healthcare, Inc. is considered risky and overvalued due to its high P/E ratio of 45 and EV to EBITDA of 20.70, which are significantly higher than its peers like Kewaunee Scientific Corp., while its low ROCE of 7.47% and ROE of 3.40% do not justify its valuation.

As of May 15, 2025, Sensus Healthcare, Inc. is considered overvalued with a P/E ratio of 45 and an EV to EBITDA of 20.70, significantly higher than industry averages and its peers, indicating a shift in market perception from very attractive to expensive.

As of May 13, 2025, Sensus Healthcare, Inc. shows a mildly bearish trend with mixed signals from key indicators, including a mildly bullish weekly MACD and bearish monthly MACD, alongside bearish Bollinger Bands and moving averages.

As of March 2022, the management team of Sensus Healthcare, Inc. includes Chairman and CEO Joseph Sardano, Directors Megan Cornish and Anthony Petrelli, and Non-Executive Independent Directors John Heinrich, William McCall, and Samuel O'Rear. They are responsible for the company's strategic direction and operations.

Sensus Healthcare, Inc. is a medical device company specializing in non-invasive treatments for skin conditions, with recent net sales of $8 million and a market cap of $79.64 million. The company reported a net profit of -$3 million for the quarter ending March 2025.

As of Jun 18, Sensus Healthcare, Inc. has a market capitalization of 79.64 million, with net sales of 39.49 million and a net profit of 1.81 million over the latest four quarters. The balance sheet shows shareholder's funds of 55.83 million and total assets of 62.19 million.